Literature DB >> 7074604

In vitro generation of tumoricidal properties in human alveolar macrophages following interaction with endotoxin.

S Sone, S Moriguchi, E Shimizu, F Ogushi, E Tsubura.   

Abstract

Human alveolar macrophages (AM) obtained by bronchoalveolar lavage from healthy nonsmoking donors exhibited primarily low levels of cytolytic activity against allogeneic tumor target cells. These AM acquired enhanced capacity to kill tumor cells following a 24-hr incubation in vitro with endotoxin [lipopolysaccharide (LPS)]. Maximal tumoricidal activity of LPS-activated AM as measured by lysis of tumor target cells was obtained after incubation with tumor cells for 72 hr. LPS-activated AM lysed allogeneic tumor cell lines of different origins but did not affect normal, nonneoplastic cells. We conclude that LPS induces human AM to become tumoricidal. This method should be useful in studies on therapeutic agents enhancing AM-mediated cytotoxicity in situ.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7074604

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Effect of Nocardia rubra cell wall skeleton on augmentation of cytotoxicity function in human pleural macrophages.

Authors:  M Sakatani; T Ogura; T Masuno; S Kishimoto; Y Yamamura
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

2.  Potentiation of direct antitumor cytotoxicity and production of tumor cytolytic factors in human blood monocytes by human recombinant interferon-gamma and muramyl dipeptide derivatives.

Authors:  S Sone; G Lopez-Berestein; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

3.  Haemophilus influenzae lipopolysaccharide-induced blood brain barrier permeability during experimental meningitis in the rat.

Authors:  B Wispelwey; A J Lesse; E J Hansen; W M Scheld
Journal:  J Clin Invest       Date:  1988-10       Impact factor: 14.808

4.  Tumor necrosis factor production by human sarcoid alveolar macrophages.

Authors:  P R Bachwich; J P Lynch; J Larrick; M Spengler; S L Kunkel
Journal:  Am J Pathol       Date:  1986-12       Impact factor: 4.307

5.  Phagocytic activity of alveolar macrophages in patients with bronchogenic carcinoma.

Authors:  J D Gangemi; G N Olsen; C Fechter; J A Hightower; C T Bauguess; L Krech
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

6.  Further studies on the differences in cytotoxicity of human peripheral blood monocytes and bronchoalveolar macrophages for cultured human lung cells.

Authors:  S Swinburne; M Moore; P Cole
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

7.  Cytotoxicity of rabbit macrophage peptides MCP-1 and MCP-2 for mouse tumor cells.

Authors:  M J Sheu; W W Baldwin; K W Brunson
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

8.  Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis.

Authors:  B W Robinson; T L McLemore; R G Crystal
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

9.  Tumoricidal activity of human monocytes activated in vitro by free and liposome-encapsulated human lymphokines.

Authors:  E S Kleinerman; A J Schroit; W E Fogler; I J Fidler
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

10.  Activation of pulmonary macrophages for fungicidal activity by gamma-interferon or lymphokines.

Authors:  E Brummer; D A Stevens
Journal:  Clin Exp Immunol       Date:  1987-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.